Why ISO 42001 Signals a Structural Shift in Life Sciences
Artificial intelligence in life sciences has moved beyond experimentation. It’s now transforming the process of evidence synthesis underpinning regulatory strategy, pricing decisions, health technology assessments, portfolio prioritization and market access modelling. These outputs will influencedecisions worth hundreds of millions, sometimes billions, of dollars. That makes governanceparamount. We need confidence that AI use – identification, gathering and summarizing of vast amounts of data for decision-making – is transparent, defensible and accountable.
Regulation is moving, but it’s not codified everywhere. Without formal, operational governance, the industry is at risk of building a house of cards.
The Collision: Regulatory Pressure Meets AI Acceleration
The life sciences sector is entering a new era of evidentiary scrutiny.
In Europe, Joint Clinical Assessments are standardizing evaluation of clinical evidence. In the United States, drug pricing negotiation mechanisms and broader policy shifts are intensifying the focus on demonstrable value and integrity.
The direction of travel is clear: stronger evidence, earlier and greater scrutiny. AI appears to offer the solution. It can interrogate literature at scale, synthesize real-world data, simulate scenarios and accelerate insight generation.
But when AI-generated outputs underpin regulatory submissions or pricing negotiations, a new question emerges: are those outputs reliable enough to defend as AI systems become more complex and increasingly opaque? We are feeding them unprecedented volumes of data and increasingly relying on their outputs as if they were neutral, deterministic engines – which, of course, they are not.
If we cannot trace data provenance, understand model behavior, validate outputs and document oversight, then acceleration becomes risk amplification.
The Illusion of Delegation
A persistent misconception is that AI governance can be outsourced or delegated through a contract to a vendor or services provider. Large organizations engage technology partners and assume responsibility has transferred, which is not always the case.
This pattern has played out before in other regulated domains. With data protection, it took years of maturation before roles and responsibilities were clearly understood and began to function properly when appropriately distributed across data controllers and processors. Accountability could not simply be delegated to one party. AI governance will follow the same path.
Implementing a transparent, shared accountability model is vital to harness the positives AI can bring.It requires explicit role clarity and cooperation across developers, deployers, and clients. Attempting to push all responsibility downstream to pharma services providers is a misunderstanding of what is required.
AI is no longer a peripheral tool; it is becoming embedded infrastructure and infrastructure demands stewardship.
Why ISO 42001 Matters
Against this backdrop, ISO 42001 certification is emerging as the global standard for Artificial Intelligence Management Systems (AIMS).
This is not a marketing badge – it is an independently audited management system that requires organizations to formalize governance across the entire AI lifecycle: design, development, deployment and monitoring. ISO 42001 helps organizations prove, not just promise, that they manage AI responsibly. Its value is in making governance operational: clear ownership, evidence of oversight and routines that hold up under scrutiny.
There is a material difference between having an AI policy in a cupboard and embedding governance into how systems are actually built, deployed and used.
Whether or not an organization pursues certification, governance becomes real when teams can answer and prove, these questions consistently:
• How is data provenance documented?
• How are model risks identified, assessed and mitigated?
• Who reviews outputs before they inform decisions?
• How is AI-generated software validated and maintained?
• What documentation exists to explain system behavior?
In high-consequence environments such as regulatory submissions, HTA engagement, or pricing negotiations, those questions are not theoretical. They are foundational.
Expertise Does Not Disappear, It Becomes Essential
A narrative circulating in parts of the technology ecosystem suggests that AI reduces reliance on experts. In life sciences, that is not just wrong, it’s dangerous. Governance frameworks and certification like ISO 42001 do not remove experts from the process; they ensure the right experts are systematically involved.
An expert-directed operating model is essential. AI can accelerate interrogation of data and surface patterns at scale, but clinical, regulatory, HEOR and medical experts remain accountable for contextual interpretation and decision framing.
The real value is not in hoovering up more information. It is in discerning the signal from the noise.As AI systems expand in scope, expertise becomes more important, not less. Governance ensures riskvisibility and defensibility and should be applied deliberately rather than assumed implicitly.
From Analysis to Next Best Action
As more organizations operationalize AI, a common request is: “Help us move from analysis, to insight, to next best action.”
Large organizations are sitting on vast repositories of untapped data. AI can interrogate those archives at unprecedented speed.
Take scenario simulation and stakeholder modelling. Simulated stakeholder engagement tools, such as Lumanity’s EMULaiTOR, are designed to stress-test evidence narratives, simulate payer perspectives and bring the patient voice into strategic decision-making in a structured way.
When governed properly, such systems can help organizations understand how different data configurations may land in a Joint Clinical Assessment, FDA submission, or pricing and reimbursement negotiation.
But those outputs must be transparent, auditable and grounded in validated data sources. ISO 42001 provides independent assurance that the management systems underpinning these AI-enabled tools meet internationally recognized standards.
This is the difference between AI as inspiration and AI as infrastructure.
A Structural Commitment, Not a Checkbox
Certification is not the end state; it is a structural commitment. The life sciences sector is still early in its AI governance maturity. Clients are increasingly asking for proof of governance in procurement processes. Formal standards will become differentiators.
The next phase of AI adoption will separate experimentation from institutionalization. Organizationsthat formalize governance early will scale responsibly. Those that wait may find themselves retrofitting controls into systems already deeply embedded in critical workflows. The choice is not between innovation and governance. It is between fragile acceleration and durable progress.
Building the Foundation for Responsible Scale
Operational maturity in AI governance requires cooperative transparency between providers and clients, with shared responsibility for how systems are used, validated and interpreted. ISO 42001 is one of the structural cornerstones of that approach.
In practice, operational governance means defining who owns AI risk, what evidence is required before outputs can inform high-impact decisions and how those controls are maintained over time.
At Lumanity, we have been operationalizing this by achieving ISO 42001 certification, becoming the first life sciences value demonstration partner to do so and embedding organization-wide controls across the AI lifecycle (design, development, deployment and monitoring). This includes role clarity, documented data provenance expectations, validation and review gates for decision-critical uses and auditable recordkeeping (including versioning and change control).
We apply these controls across Expert-Directed AI use cases that support decision-critical work across the product lifecycle: AI accelerates synthesis and scenario exploration, while domain experts remain accountable for what is ultimately defensible under external scrutiny.
Combined with expert oversight and governed deployment practices, this enables organizations to harness AI’s power while maintaining defensibility, transparency and trust. If AI is going to underpin billion-dollar decisions and accelerate access to life-changing medicines, then its foundations must be sound. Otherwise, we risk building higher and faster on unstable ground.
In life sciences, that is not a risk worth taking.
